The role of coagulation and platelets in colon cancer-associated thrombosis

Annachiara Mitrugno, Samuel Tassi Yunga, Joanna L. Sylman, Jevgenia Zilberman-Rudenko, Toshiaki Shirai, Jessica F. Hebert, Robert Kayton, Ying Zhang, Xiaolin Nan, Joseph J. Shatzel, Sadik Esener, Matthew T. Duvernay, Heidi E. Hamm, Andras Gruber, Craig D. Williams, Yumie Takata, Randall Armstrong, Terry Morgan, Owen McCarty

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cancer-associated thrombosis is a common first presenting sign of malignancy and is currently the second leading cause of death in cancer patients after their malignancy. However, the molecular mechanisms underlying cancer-associated thrombosis remain undefined. In this study, we aimed to develop a better understanding of how cancer cells affect the coagulation cascade and platelet activation to induce a prothrombotic phenotype. Our results show that colon cancer cells trigger platelet activation in a manner dependent on cancer cell tissue factor (TF) expression, thrombin generation, activation of the protease-activated receptor 4 (PAR4) on platelets and consequent release of ADP and thromboxane A2. Platelet-colon cancer cell interactions potentiated the release of platelet-derived extracellular vesicles (EVs) rather than cancer cell-derived EVs. Our data show that single colon cancer cells were capable of recruiting and activating platelets and generating fibrin in plasma under shear flow. Finally, in a retrospective analysis of colon cancer patients, we found that the number of venous thromboembolism events was 4.5 times higher in colon cancer patients than in a control population. In conclusion, our data suggest that platelet-cancer cell interactions and perhaps platelet procoagulant EVs may contribute to the prothrombotic phenotype of colon cancer patients. Our work may provide rationale for targeting platelet-cancer cell interactions with PAR4 antagonists together with aspirin and/or ADP receptor antagonists as a potential intervention to limit cancer-associated thrombosis, balancing safety with efficacy.

Original languageEnglish (US)
Pages (from-to)C264-C273
JournalAmerican journal of physiology. Cell physiology
Volume316
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Colonic Neoplasms
Thrombosis
Blood Platelets
Neoplasms
Cell Communication
Platelet Activation
Purinergic P2Y Receptor Antagonists
Phenotype
Thromboxane A2
Venous Thromboembolism
Thromboplastin
Fibrin
Thrombin
Adenosine Diphosphate
Aspirin
Cause of Death
Safety

Keywords

  • aspirin
  • cancer
  • coagulation
  • PAR4
  • platelets
  • thrombosis

ASJC Scopus subject areas

  • Physiology
  • Cell Biology

Cite this

Mitrugno, A., Tassi Yunga, S., Sylman, J. L., Zilberman-Rudenko, J., Shirai, T., Hebert, J. F., ... McCarty, O. (2019). The role of coagulation and platelets in colon cancer-associated thrombosis. American journal of physiology. Cell physiology, 316(2), C264-C273. https://doi.org/10.1152/ajpcell.00367.2018

The role of coagulation and platelets in colon cancer-associated thrombosis. / Mitrugno, Annachiara; Tassi Yunga, Samuel; Sylman, Joanna L.; Zilberman-Rudenko, Jevgenia; Shirai, Toshiaki; Hebert, Jessica F.; Kayton, Robert; Zhang, Ying; Nan, Xiaolin; Shatzel, Joseph J.; Esener, Sadik; Duvernay, Matthew T.; Hamm, Heidi E.; Gruber, Andras; Williams, Craig D.; Takata, Yumie; Armstrong, Randall; Morgan, Terry; McCarty, Owen.

In: American journal of physiology. Cell physiology, Vol. 316, No. 2, 01.02.2019, p. C264-C273.

Research output: Contribution to journalArticle

Mitrugno, A, Tassi Yunga, S, Sylman, JL, Zilberman-Rudenko, J, Shirai, T, Hebert, JF, Kayton, R, Zhang, Y, Nan, X, Shatzel, JJ, Esener, S, Duvernay, MT, Hamm, HE, Gruber, A, Williams, CD, Takata, Y, Armstrong, R, Morgan, T & McCarty, O 2019, 'The role of coagulation and platelets in colon cancer-associated thrombosis', American journal of physiology. Cell physiology, vol. 316, no. 2, pp. C264-C273. https://doi.org/10.1152/ajpcell.00367.2018
Mitrugno A, Tassi Yunga S, Sylman JL, Zilberman-Rudenko J, Shirai T, Hebert JF et al. The role of coagulation and platelets in colon cancer-associated thrombosis. American journal of physiology. Cell physiology. 2019 Feb 1;316(2):C264-C273. https://doi.org/10.1152/ajpcell.00367.2018
Mitrugno, Annachiara ; Tassi Yunga, Samuel ; Sylman, Joanna L. ; Zilberman-Rudenko, Jevgenia ; Shirai, Toshiaki ; Hebert, Jessica F. ; Kayton, Robert ; Zhang, Ying ; Nan, Xiaolin ; Shatzel, Joseph J. ; Esener, Sadik ; Duvernay, Matthew T. ; Hamm, Heidi E. ; Gruber, Andras ; Williams, Craig D. ; Takata, Yumie ; Armstrong, Randall ; Morgan, Terry ; McCarty, Owen. / The role of coagulation and platelets in colon cancer-associated thrombosis. In: American journal of physiology. Cell physiology. 2019 ; Vol. 316, No. 2. pp. C264-C273.
@article{fd54bbd2beed42f99c15239a4f91e559,
title = "The role of coagulation and platelets in colon cancer-associated thrombosis",
abstract = "Cancer-associated thrombosis is a common first presenting sign of malignancy and is currently the second leading cause of death in cancer patients after their malignancy. However, the molecular mechanisms underlying cancer-associated thrombosis remain undefined. In this study, we aimed to develop a better understanding of how cancer cells affect the coagulation cascade and platelet activation to induce a prothrombotic phenotype. Our results show that colon cancer cells trigger platelet activation in a manner dependent on cancer cell tissue factor (TF) expression, thrombin generation, activation of the protease-activated receptor 4 (PAR4) on platelets and consequent release of ADP and thromboxane A2. Platelet-colon cancer cell interactions potentiated the release of platelet-derived extracellular vesicles (EVs) rather than cancer cell-derived EVs. Our data show that single colon cancer cells were capable of recruiting and activating platelets and generating fibrin in plasma under shear flow. Finally, in a retrospective analysis of colon cancer patients, we found that the number of venous thromboembolism events was 4.5 times higher in colon cancer patients than in a control population. In conclusion, our data suggest that platelet-cancer cell interactions and perhaps platelet procoagulant EVs may contribute to the prothrombotic phenotype of colon cancer patients. Our work may provide rationale for targeting platelet-cancer cell interactions with PAR4 antagonists together with aspirin and/or ADP receptor antagonists as a potential intervention to limit cancer-associated thrombosis, balancing safety with efficacy.",
keywords = "aspirin, cancer, coagulation, PAR4, platelets, thrombosis",
author = "Annachiara Mitrugno and {Tassi Yunga}, Samuel and Sylman, {Joanna L.} and Jevgenia Zilberman-Rudenko and Toshiaki Shirai and Hebert, {Jessica F.} and Robert Kayton and Ying Zhang and Xiaolin Nan and Shatzel, {Joseph J.} and Sadik Esener and Duvernay, {Matthew T.} and Hamm, {Heidi E.} and Andras Gruber and Williams, {Craig D.} and Yumie Takata and Randall Armstrong and Terry Morgan and Owen McCarty",
year = "2019",
month = "2",
day = "1",
doi = "10.1152/ajpcell.00367.2018",
language = "English (US)",
volume = "316",
pages = "C264--C273",
journal = "American Journal of Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - The role of coagulation and platelets in colon cancer-associated thrombosis

AU - Mitrugno, Annachiara

AU - Tassi Yunga, Samuel

AU - Sylman, Joanna L.

AU - Zilberman-Rudenko, Jevgenia

AU - Shirai, Toshiaki

AU - Hebert, Jessica F.

AU - Kayton, Robert

AU - Zhang, Ying

AU - Nan, Xiaolin

AU - Shatzel, Joseph J.

AU - Esener, Sadik

AU - Duvernay, Matthew T.

AU - Hamm, Heidi E.

AU - Gruber, Andras

AU - Williams, Craig D.

AU - Takata, Yumie

AU - Armstrong, Randall

AU - Morgan, Terry

AU - McCarty, Owen

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Cancer-associated thrombosis is a common first presenting sign of malignancy and is currently the second leading cause of death in cancer patients after their malignancy. However, the molecular mechanisms underlying cancer-associated thrombosis remain undefined. In this study, we aimed to develop a better understanding of how cancer cells affect the coagulation cascade and platelet activation to induce a prothrombotic phenotype. Our results show that colon cancer cells trigger platelet activation in a manner dependent on cancer cell tissue factor (TF) expression, thrombin generation, activation of the protease-activated receptor 4 (PAR4) on platelets and consequent release of ADP and thromboxane A2. Platelet-colon cancer cell interactions potentiated the release of platelet-derived extracellular vesicles (EVs) rather than cancer cell-derived EVs. Our data show that single colon cancer cells were capable of recruiting and activating platelets and generating fibrin in plasma under shear flow. Finally, in a retrospective analysis of colon cancer patients, we found that the number of venous thromboembolism events was 4.5 times higher in colon cancer patients than in a control population. In conclusion, our data suggest that platelet-cancer cell interactions and perhaps platelet procoagulant EVs may contribute to the prothrombotic phenotype of colon cancer patients. Our work may provide rationale for targeting platelet-cancer cell interactions with PAR4 antagonists together with aspirin and/or ADP receptor antagonists as a potential intervention to limit cancer-associated thrombosis, balancing safety with efficacy.

AB - Cancer-associated thrombosis is a common first presenting sign of malignancy and is currently the second leading cause of death in cancer patients after their malignancy. However, the molecular mechanisms underlying cancer-associated thrombosis remain undefined. In this study, we aimed to develop a better understanding of how cancer cells affect the coagulation cascade and platelet activation to induce a prothrombotic phenotype. Our results show that colon cancer cells trigger platelet activation in a manner dependent on cancer cell tissue factor (TF) expression, thrombin generation, activation of the protease-activated receptor 4 (PAR4) on platelets and consequent release of ADP and thromboxane A2. Platelet-colon cancer cell interactions potentiated the release of platelet-derived extracellular vesicles (EVs) rather than cancer cell-derived EVs. Our data show that single colon cancer cells were capable of recruiting and activating platelets and generating fibrin in plasma under shear flow. Finally, in a retrospective analysis of colon cancer patients, we found that the number of venous thromboembolism events was 4.5 times higher in colon cancer patients than in a control population. In conclusion, our data suggest that platelet-cancer cell interactions and perhaps platelet procoagulant EVs may contribute to the prothrombotic phenotype of colon cancer patients. Our work may provide rationale for targeting platelet-cancer cell interactions with PAR4 antagonists together with aspirin and/or ADP receptor antagonists as a potential intervention to limit cancer-associated thrombosis, balancing safety with efficacy.

KW - aspirin

KW - cancer

KW - coagulation

KW - PAR4

KW - platelets

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85061121745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061121745&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00367.2018

DO - 10.1152/ajpcell.00367.2018

M3 - Article

VL - 316

SP - C264-C273

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6143

IS - 2

ER -